Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Docetaxel and Oxaliplatin in Metastatic Cisplatin-resistant TCC
NCT03159143Phase 2Completed
- Start
- Dec 2004
- Primary completion
- Jun 2009
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of docetaxel and oxaliplatin in transitional cell carcinoma (TCC). Primary endpoint: Response Rate up to 4 years. Started Dec 2004; status: completed.
02
Drugs
docetaxeloxaliplatin
03
Conditions
transitional cell carcinoma (TCC)
Beyond the preview
Go deeper on NCT03159143.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03159143.